文献速递角膜与眼表疾病

雷帕霉素滴眼液在干燥综合征小鼠模型中抑制泪腺炎症

Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

研究在雄性非肥胖糖尿病(NOD)小鼠干燥综合征模型中,从8周龄起每日两次给予雷帕霉素或PEG-DSPE(载体)滴眼液共12周。雷帕霉素组泪腺淋巴细胞浸润较载体组显著减少3.8倍(P=0.0001),泪液Cathepsin S活性在泪液中降低3.75倍(P<0.0001)、在泪腺裂解液中降低1.68倍(P=0.003),并增加泪液分泌、减少角膜荧光素染色。作者认为局部雷帕霉素可能用于治疗干燥综合征相关干眼。

要点

  • 雷帕霉素滴眼液使NOD小鼠泪腺淋巴细胞浸润较载体组减少3.8倍(P=0.0001)。
  • 雷帕霉素组泪液Cathepsin S活性较载体组降低3.75倍(P<0.0001),泪腺裂解液中降低1.68倍(P=0.003)。
  • 雷帕霉素增加泪液分泌并减少角膜荧光素染色,作者认为对干燥综合征相关干眼有潜在治疗价值。

核心结论

  • 作者认为局部雷帕霉素可减轻自身免疫介导的泪腺炎症,同时改善眼表完整性和泪液分泌,因此对干燥综合征相关干眼具有治疗潜力。

研究设计与样本

  • 研究在雄性非肥胖糖尿病(NOD)小鼠干燥综合征模型中进行,从8周龄起每日两次给予雷帕霉素或PEG-DSPE(载体)滴眼液,共12周。
  • 雷帕霉素采用聚乙二醇-二硬脂酰磷脂酰乙醇胺(PEG-DSPE)胶束制剂以保持溶解性。
  • 检测指标包括泪液Cathepsin S、泪腺组织学、干燥综合征相关基因的实时定量PCR、酚红棉线泪液分泌和角膜荧光素染色。

主要发现

  • 治疗12周后,雷帕霉素组泪腺淋巴细胞浸润较载体组显著减少3.8倍(P=0.0001)。
  • 雷帕霉素组泪液Cathepsin S活性较载体组在泪液中降低3.75倍(P<0.0001),在泪腺裂解液中降低1.68倍(P=0.003)。
  • 雷帕霉素(而非载体)治疗12周后增加泪液分泌并减少角膜荧光素染色。
  • 雷帕霉素显著改变多个与干燥综合征发病相关基因的表达,包括主要组织相容性复合体II类、TNF-α、IFN-γ、IL-12a以及自噬效应因子Akt3。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy of topical rapamycin in treating autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. METHODS: We developed rapamycin in a poly(ethylene glycol)-distearoyl phosphatidylethanolamine (PEG-DSPE) micelle formulation to maintain solubility. Rapamycin or PEG-DSPE eye drops (vehicle) were administered in a well-established Sjögren's syndrome disease model, the male nonobese diabetic (NOD) mice, twice daily for 12 weeks starting at 8 weeks of age. Mouse tear fluid was collected and tear Cathepsin S, a putative tear biomarker for Sjögren's syndrome, was measured. Lacrimal glands were retrieved for histological evaluation, and quantitative real-time PCR of genes associated with Sjögren's syndrome pathogenesis. Tear secretion was measured using phenol red threads, and corneal fluorescein staining was used to assess corneal integrity. RESULTS: Lymphocytic infiltration of lacrimal glands from rapamycin-treated mice was significantly (P = 0.0001) reduced by 3.8-fold relative to vehicle-treated mice after 12 weeks of treatment. Rapamycin, but not vehicle, treatment increased tear secretion and decreased corneal fluorescein staining after 12 weeks. In rapamycin-treated mice, Cathepsin S activity was significantly reduced by 3.75-fold in tears (P < 0.0001) and 1.68-fold in lacrimal gland lysates (P = 0.003) relative to vehicle-treated mice. Rapamycin significantly altered the expression of several genes linked to Sjögren's syndrome pathogenesis, including major histocompatibility complex II, TNF-α, IFN-γ, and IL-12a, as well as Akt3, an effector of autophagy. CONCLUSIONS: Our findings suggest that topical rapamycin reduces autoimmune-mediated lacrimal gland inflammation while improving ocular surface integrity and tear secretion, and thus has potential for treating Sjögren's syndrome-associated dry eye.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Shah M, Edman MC, Reddy Janga S, et al. Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. Invest Ophthalmol Vis Sci. 2017. PMID: 28122086. doi:10.1167/iovs.16-19159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。